Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice

European Journal of Pharmacology

Volumn 404, Issue 1-2, 2000, Pages 239-245

  Ahrén, Bo ^a   Holst, Jens J ^b   Mårtensson, Hans ^c   Balkan, Börk ^d  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HELSINGBORG HOSPITAL   (Sweden)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Diabetes; Dipeptidyl peptidase IV; Glucagon like peptide 1 (GLP 1); Glucose tolerance; Glucose tolerance, impaired; Insulin secretion; Type 2

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; UNCLASSIFIED DRUG; VALINE PYRROLIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; BODY WEIGHT; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; INSULIN; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; PROTEIN PRECURSORS;

EID: 0034666562     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00600-2     Document Type: Article

References (29)

1. Ahrén B. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. BioEssays. 20:1998;642-651.
2. Ahrén B. Potentiators and inhibitors of insulin secretion. Howell S.L. Advances in Molecular and Cell Biology. The Biology of the Pancreatic B cell. vol. 29:1999;175-197 JAI Press, Greenwich, Ct.
3. Ahrén B., Lundquist I. Effects of peptide HI on basal and stimulated insulin and glucagon secretion in the mouse. Neuropeptides. 11:1988;159-162.
4. Ahrén B., Pacini G. Glucagon-like peptide-1 stimulates insulin secretion and glucose effectiveness in mice. Am. J. Physiol. 277:1999;E996-E1004.
5. Ahrén B., Larsson H., Holst J.J. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;473-478.
6. Ahrén B., Simonsson E., Scheurink A.J.W., Mulder H., Myrsén U., Sundler F. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism. 46:1997;97-106.
7. Balkan B., Kwasnik L., Miserendino R., Holst J.J., Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia. 42:1999;1324-1331.
8. Deacon C.F., Hughes T.E., Holst J.J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anesthetized pig. Diabetes. 47:1998;764-769.
9. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80:1995;952-957.
10. Deacon C.F., Pridal L., Klarskov L., Olesen M., Holst J.J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am. J. Physiol. 271:1996;E458-E464.
11. (7-36) amide: Influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas. 6:1991;208-215.
12. Gutniak M., Ørskov C., Holst J., Ahrén B., Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326:1992;1316-1322.
13. Gutniak M.K., Larsson H., Sanders S.W., Juneskans O., Holst J.J., Ahrén B. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care. 20:1997;1874-1879.
14. Hansen L., Deacon C.F., Ørskov C., Holst J.J Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV activity in the capillaries supplying the L-cells of the porcine intestine. Endocrinology. 140:1999;5356-5363.
15. Holst J.J., Deacon C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 47:1998;1663-1670.
16. Holst J.J., Ørskov A.C., Schwartz T.W., Nielsen O.V. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 211:1987;169-174.
17. Juntti-Berggren L., Pigon J., Karpe F., Hamsten A., Gutniak M., Vignati L., Efendic S. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care. 19:1996;1200-1206.
18. Kieffer T.J., McIntosh C.H.S., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 136:1995;3585-3596.
19. Knudsen L.B., Pridal L. Glucagon-like peptide-1 (9-36)amide is a major metabolite of glucagon-like peptide-1 (7-36)amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. 318:1996;429-435.
20. Kreymann B., Ghtei M.A., Williams G., Bloom S.R. Glucagon-like peptide 1 7-36: a physiological incretin in man. Lancet. 2:1987;1300-1303.
21. Larsson H., Holst J.J., Ahrén B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol. Scand. 160:1997;413-422.
22. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85:1999;9-24.
23. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, and peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214:1993;829-835.
24. Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Ørskov C., Ritzel R., Schmiegel W.H. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 273:1997;E981-988.
25. Nauck M.A. Is glucagon-like peptide 1 an incretin hormone? Diabetologia. 42:1999;373-379.
26. Ørskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia. 35:1992;701-711.
27. Pederson R.A., White H.A., Schlenzig D., Pauly R.P., McIntosh C.H.S., Demuth H.U. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes. 47:1998;1253-1258.
28. Sugiyama K., Manaka H., Kato T., Yamatani K., Tominaga M., Sasaki H. Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorpion. Digestion. 55:1994;24-28.
29. Willms B., Werner J., Holst J.J., Ørskov C., Creutzfeldt W., Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36)amide in type 2 (non-insulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 81:1996;327-332.